TFF Pharmaceuticals to Present at the BIO CEO & Investor Digital Conference
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a biopharmaceutical firm specializing in innovative drug products, will participate in the 2021 BIO CEO & Investor Digital Conference from February 16-18, 2021. CEO Glenn Mattes will present a pre-recorded session available on-demand for 30 days to registered attendees. TFF Pharmaceuticals utilizes its patented Thin Film Freezing (TFF) technology to enhance drug solubility and absorption, focusing on inhalation delivery to the deep lung, with potential drug deposition as high as 75%. The company aims to expand its pipeline through collaborations.
- None.
- None.
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, will participate in the 2021 BIO CEO & Investor Digital Conference, being held virtually on February 16-18, 2021.
Glenn Mattes, President & CEO of TFF Pharmaceuticals, is scheduled to give a pre-recorded company presentation at the conference. The recording will be available on-demand to registered conference attendees via the BIO conference portal for 30 days and can be accessed in the Investor Relations section of the TFF Pharmaceuticals website.
The Company will also participate in investor and partnering meetings with conference attendees during the event.
About TFF Pharmaceuticals’ Thin Film Freezing technology platform
TFF Pharmaceuticals’ Thin Film Freezing (TFF) platform was designed to improve the solubility and absorption of poorly water-soluble drugs and is particularly suited to generate dry powder particles with properties targeted for inhalation delivery, especially to the deep lung, an area of extreme interest in respiratory medicine. The TFF process results in a “Brittle Matrix Particle,” which possesses low bulk density, high surface area, and typically an amorphous morphology, allowing the particles to supersaturate when contacting the target site, such as lung tissue. Based upon laboratory experiments the aerodynamic properties of the particles are such that the portion of a drug deposited to the deep lung has the potential to reach as high as 75 percent.
About TFF Pharmaceuticals
TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform. Early testing confirms that the TFF platform can significantly improve the solubility and absorption of poorly water-soluble drugs, a class of drugs that comprises approximately one-third of the major pharmaceuticals worldwide, thereby improving their pharmacokinetics. TFF Pharmaceuticals has two lead drug candidates: Voriconazole Inhalation Powder and Tac-Lac Inhalation Powder. The Company plans to add to this pipeline by collaborating with large pharmaceutical partners. The TFF Platform is protected by 42 patents issued or pending in the US and internationally. To learn more about TFF Pharmaceuticals and its product candidates, visit the Company’s website at https://tffpharma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210212005267/en/
FAQ
When is TFF Pharmaceuticals participating in the BIO CEO & Investor Digital Conference?
Who will present for TFF Pharmaceuticals at the BIO CEO & Investor Digital Conference?
What is the focus of TFF Pharmaceuticals' Thin Film Freezing technology?
What is the potential drug deposition rate for TFF Pharmaceuticals' inhalation products?
What drug candidates does TFF Pharmaceuticals currently have?
